Determinants of participation in a post-hospitalization physical exercise program for older adults.

BACKGROUND: Older patients often experience a decline in physical function and cognitive status after hospitalization. Although interventions involving physical exercise are effective in improving functional performance, participation in physical exercise interventions among older individuals is low. We aimed to identify factors that contribute to exercise refusal among post-hospitalized older patients. METHODS: A cross-sectional study of recruitment data from a randomized controlled trial was conducted involving 495 hospitalized people ≥70 years old. Sociodemographic and clinical data were obtained from the Basque Public Health System database. We determined physical function with the Short Physical Performance Battery (SPPB), nutritional status with the Mini-Nutritional Assessment, frailty according to the Fried phenotype criteria, and cognitive function with the Short Portable Mental Status Questionnaire (SPMSQ). Student's t, Mann-Whitney U, or chi-squared tests were applied for bivariate analysis. Parameters significantly associated with participation were introduced in a logistic multivariate regression model. RESULTS: Among the analyzed patients, 88.8% declined participation in the physical exercise program. Multivariate regression revealed that older age (OR: 1.13; 95% CI: 1.07-1.19), poor nutritional status (OR: 0.81; 95% CI: 0.69-0.95), and reduced home accessibility (OR: 0.27; 95% CI: 0.08-0.94) were predictors of participation refusal. Moreover, patients who declined participation had worse performance on the SPPB (P < 0.05) and its tests of balance, leg strength, and walking speed (P < 0.05). No differences were found between groups in other variables. CONCLUSIONS: This study confirms low participation of older adults in a post-hospitalization physical exercise program. Non-participation was associated with increased age, poor nutritional status, and reduced home accessibility. Our findings support the need for intervention design that accounts for these factors to increase older patient participation in beneficial exercise programs. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12619000093189 , (date: January 22, 2019, retrospectively registered).

Effects of Leucine-Enriched Whey Protein Supplementation on Physical Function in Post-Hospitalized Older Adults Participating in 12-Weeks of Resistance Training Program: A Randomized Controlled Trial.

Age-related strength and muscle mass loss is further increased after acute periods of inactivity. To avoid this, resistance training has been proposed as an effective countermeasure, but the additional effect of a protein supplement is not so clear. The aim of this study was to examine the effect of a whey protein supplement enriched with leucine after resistance training on muscle mass and strength gains in a post-hospitalized elderly population. A total of 28 participants were included and allocated to either protein supplementation or placebo supplementation following resistance training for 12 weeks (2 days/week). Physical function (lower and upper body strength, aerobic capacity and the Short Physical Performance Battery (SPPB) test), mini nutritional assessment (MNA) and body composition (Dual X-ray Absorptiometry) were assessed at baseline and after 12 weeks of resistance training. Both groups showed improvements in physical function after the intervention (p < 0.01), but there were no further effects for the protein group (p > 0.05). Muscle mass did not improve after resistance training in either group (p > 0.05). In conclusion, 12 weeks of resistance training are enough to improve physical function in a post-hospitalized elderly population with no further benefits for the protein-supplemented group.

Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.

BACKGROUND: Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion. METHODS: Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI). RESULTS: A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9). CONCLUSIONS: A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.

Factores asociados con la no realizacion de la prueba de la tuberculina en una cohorte de pacientes VIH positivos / Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people

Introduccion Dada la asociacion entre tuberculosis (TB) e infeccion por VIH, la realizacion del Mantoux esta indicada en todo paciente infectado con VIH. Este articulo analiza la frecuencia de no realizacion de la prueba de la tuberculina y sus factores asociados en una cohorte de infectados con VIH. Pacientes y metodos Entre 2000-C2002 se identifico en 10 hospitales a todos los pacientes infectados con VIH y no seguidos previamente, de forma regular, en consultas especificas. Se recogio informacion de la historia clinica sobre realizacion del Mantoux y otras variables. Se calculo el porcentaje de no realizacion del Mantoux y los factores asociados mediante la utilizacion como medida de asociacion de la odds ratio (OR) y su intervalo de confianza (IC) del 95%. Para el analisis multivariante se ajusto un modelo de regresion logistica. Resultados Mil doscientos cuarenta y dos pacientes cumplieron criterios de inclusion y a 185 pacientes no se les realizo el Mantoux (el 17,6% de aquellos en los que estaba indicado). La probabilidad de no realizacion del Mantoux fue mayor en usuarios de drogas (OR: 2,6; IC del 95%: 1,1¨C6,5) y menor entre los desempleados (OR: 0,6; IC del 95%: 0,3¨C1,0), aquellos con mas de 200 CD4 (CD4 200¨C499: OR: 0,5; IC del 95%: 0,3¨C0,9; CD4 ¡Ý500: OR: 0,3; IC del 95%: 0,2¨C0,6) y los contactos con enfermos tuberculosos (OR: 0,2; IC del 95%: 0,1¨C0,5).ConclusionesEl porcentaje de no realizacion del Mantoux es bastante elevado. La no realizacion del Mantoux parece asociarse con las expectativas del medico, tanto sobre el resultado de la prueba como sobre la correcta cumplimentacion del tratamiento preventivo anti-TB por el paciente ( AU)

Introduction Tuberculin skin testing (TST) for tuberculosis (TB) is recommended for all patients with HIV infection because of the known relationship between these two conditions. In this report we analyze the incidence and variables associated with non-prescription of TST in a cohort of HIV-infected people. Patients and methods Longitudinal study conducted between 2000 and 2002 at 10 HIV hospital-based clinics. All HIV-infected patients who had not been regularly followed-up previously in dedicated clinics were identified. Data about TST and other variables related to TB were obtained from the clinical records. We calculated the percentage of patients who did not undergo TST and the associated factors, using odds ratios (ORs) and the 95% CI to investigate associations. A multivariate logistic regression analysis was performed. Results A total of 1242 patients met the inclusion criteria. TST was not performed in 185 patients (17.6% of those eligible). The fact of being an intravenous drug abuser was associated with a higher probability of TST non-prescription (OR: 2.6, 95% CI 1.1¨C6.5), whereas being unemployed (OR: 0.6, 95% CI 0.3¨C1.0), having a CD4 cell count >200 (CD4 200¨C499: OR 0.5, 95% CI 0.3¨C0.9. CD4¡Ý500: OR 0.3, 95% CI 0.2¨C0.6), and contact with persons with TB (OR 0.2, 95% CI 0.1¨C0.5) were associated with a lower probability. ConclusionsIn this study, the percentage of TST non-prescription was quite high. The results suggest that TST non-prescription in this population is related to the clinicians¡¯ expectations regarding the results of the test and the patients¡¯ adherence to treatment for latent TB infection(AU)

[Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]. / Factores asociados con la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos.

INTRODUCTION: Tuberculin skin testing (TST) for tuberculosis (TB) is recommended for all patients with HIV infection because of the known relationship between these two conditions. In this report we analyze the incidence and variables associated with non-prescription of TST in a cohort of HIV-infected people. PATIENTS AND METHODS: Longitudinal study conducted between 2000 and 2002 at 10 HIV hospital-based clinics. All HIV-infected patients who had not been regularly followed-up previously in dedicated clinics were identified. Data about TST and other variables related to TB were obtained from the clinical records. We calculated the percentage of patients who did not undergo TST and the associated factors, using odds ratios (ORs) and the 95% CI to investigate associations. A multivariate logistic regression analysis was performed. RESULTS: A total of 1242 patients met the inclusion criteria. TST was not performed in 185 patients (17.6% of those eligible). The fact of being an intravenous drug abuser was associated with a higher probability of TST non-prescription (OR: 2.6, 95% CI 1.1-6.5), whereas being unemployed (OR: 0.6, 95% CI 0.3-1.0), having a CD4 cell count >200 (CD4 200-499: OR 0.5, 95% CI 0.3-0.9. CD4> or =500: OR 0.3, 95% CI 0.2-0.6), and contact with persons with TB (OR 0.2, 95% CI 0.1-0.5) were associated with a lower probability. CONCLUSIONS: In this study, the percentage of TST non-prescription was quite high. The results suggest that TST non-prescription in this population is related to the clinicians' expectations regarding the results of the test and the patients' adherence to treatment for latent TB infection.

Nephrogenic systemic fibrosis in a patient with a p-ANCA systemic vasculitis

La fibrosis sistémica nefrogénica (FSN) es una entidad de origen desconocido caracterizada por un incremento de la fibrosis cutánea. La mayoría de los casos se han descrito en pacientes con fracaso renal agudo o crónico. Las alteraciones cutáneas incluyen pápulas y placas dérmicas engrosadas e induradas distribuidas por las extremidades y el tronco. El estudio histológico pone de manifiesto un incremento en la dermis del número de células tipo fibroblasto acompañado de depósito de mucina. En la mayoría de los casos existe el antecedente reciente de exposición a agentes de contraste tipo gadolinio. Describimos una paciente que presenta los hallazgos clínicos y patológicos característicos de la FSN después de un fracaso renal agudo en el contexto de una vasculitis asociada a anticuerpos anticitoplasma de los neutrófilos (AU)

Nephrogenic systemic fibrosis (NSF) is a fibrosing skin condition of unknown origin. Most cases have been described in patients with acute or chronic renal failure. The cutaneous changes include firm and thickened, indurate skin plaques and papules on the extremities and trunk. Histopathology typically shows an increase in dermal fibroblast-like cells associated with mucin deposition. Previous exposition to gadolinium-based contrast agents was closely associated with its onset. We described a patient with the clinical and pathologic picture of NSF presented after an acute renal failure in the course of a perinuclear antineutrophil cytoplasmic antibodies associated systemic vasculitis (AU)

Nephrogenic systemic fibrosis in a patient with a p-ANCA systemic vasculitis.

Nephrogenic systemic fibrosis (NSF) is a fibrosing skin condition of unknown origin. Most cases have been described in patients with acute or chronic renal failure. The cutaneous changes include firm and thickened, indurate skin plaques and papules on the extremities and trunk. Histopathology typically shows an increase in dermal fibroblast-like cells associated with mucin deposition. Previous exposition to gadolinium-based contrast agents was closely associated with its onset. We described a patient with the clinical and pathologic picture of NSF presented after an acute renal failure in the course of a perinuclear antineutrophil cytoplasmic antibodies associated systemic vasculitis.

Rickettsia monacensis and human disease, Spain.

We identified Rickettsia monacensis as a cause of acute tickborne rickettsiosis in 2 humans. Its pathogenic role was assessed by culture and detection of the organism in patients' blood samples. This finding increases the number of recognized human rickettsial pathogens and expands the known geographic distribution of Mediterranean spotted fever-like cases.

Seroactivity of Crohn´s disease patients to mycobacterial antigens: original data and analytical review of early literature

La etiología micobacteriana de la enfermedad de Crohn es objeto de discusión desde hace mucho tiempo yse han publicado diversos trabajos al respecto. En este artículo se lleva a cabo un análisis crítico de la informacióngenerada sobre la respuesta humoral frente a antígenos de Mycobacterium en pacientes con enfermedad de Crohn, colitis ulcerosa y tuberculosis y en controles sanos, durante la década siguiente a las primeras sospechasa comienzos de 1980s. Además incluimos resultados de nuestro laboratorio no publicados anteriormente, sobrela respuesta humoral de pacientes con enfermedad de Crohn, colitis ulcerosa y tuberculosis y en controles sanosa un ELISA con el antígeno PPA-3 de paratuberculosis. Nuestro estudio de meta-análisis indica que el análisisestadístico de los datos en alguno de los estudios realizados no fue adecuado y que globalmente los pacientesde Crohn tienen una respuesta significativa a antígenos de micobacterianos, que es similar a la de pacientes detuberculosis (p<0,01)

The mycobacterial etiology of Crohn’s disease has longtime been the subject of discussion and severalstudies on this issue have been published. In this paper we set out to critically analyze reports on the humoralresponse against mycobacterial antigens among Crohn’s disease patients and matched samples of ulcerativecolitis, tuberculosis, and healthy controls, published during the decade that followed initial suspicions in theearly-mid 1980s. We also provide our own previously unpublished results of the humoral response of Crohn’sdisease, ulcerative colitis, and tuberculosis patients and healthy controls to an adapted paratuberculosis (PPA-3 antigen) ELISA. Our study indicate that statistical analysis of some studies were not adequate, and that ageneral significantly (p<0.01) increased reactivity against mycobacterial antigens could be observed in thecombined analysis of all available data (meta-analysis). The reactivity of Crohn’s patients did not signficantlydiffer from reactivity of tuberculosis patients against mycobacterial antigens